Andexanet alfa - Portola Pharmaceuticals

Drug Profile

Andexanet alfa - Portola Pharmaceuticals

Alternative Names: AndexXa; AnXa; Coagulation factor Xa (recombinant), inactivated-zhzo; IndexXa; PRT-064445; PRT-4445; PRT-44545; Recombinant factor-Xa-Portola; rfXa-inhibitor-antidote

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Portola Pharmaceuticals
  • Class Antidotes; Antihaemorrhagics; Disulfides; Recombinant proteins
  • Mechanism of Action Blood coagulation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemorrhage
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Haemorrhage

Most Recent Events

  • 03 May 2018 Portola Pharmaceuticals expects a decision from the European Commission for the MAA of andexanet alfa in early 2019
  • 03 May 2018 Portola Pharmaceuticals plans to launch andexanet alfa in the US under an early supply programme with Generation 1 product in June 2018
  • 03 May 2018 Portola Pharmaceuticals plans a commercial launch of andexanet alfa upon FDA approval of its Generation 2 manufacturing process in early 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top